In brief: On October 30, 2026, the DEA placed centanafadine, sold as Simtriyo, into Schedule III of the Controlled Substances Act. Simtriyo is the first genuinely new drug class approved for ADHD in decades: a triple reuptake inhibitor that is not an amphetamine and not methylphenidate. The lower schedule means refills are allowed and prescribing is less encumbered than for Adderall or Ritalin, which are Schedule II. It is still a stimulant with a boxed warning, it has never been tested head to head against the older drugs, and it will be brand-only for years.
What actually happened
The sequence of events matters, because it explains why the drug reached pharmacies at all.
- July 18, 2026: HHS sent the DEA its recommendation that centanafadine be controlled at Schedule III.
- July 24, 2026: The FDA approved Simtriyo for ADHD in adults and in children 6 and older who weigh at least 20 kg, about 44 pounds.
- October 30, 2026: The DEA published an interim final rule placing centanafadine in Schedule III, effective that day.
Centanafadine had never been scheduled or legally marketed before, so this was its first scheduling action. The DEA used an expedited pathway created by a 2015 law, the Improving Regulatory Transparency for New Medical Therapies Act, which lets a new drug be scheduled immediately after FDA approval so it is not stranded in regulatory limbo while a full notice-and-comment rulemaking grinds along.
The rule is an interim final rule, which is why you may see headlines suggesting the schedule is not final. The DEA will accept public comments and hearing requests until November 30, 2026, then issue a final rule. Schedule III is the expected outcome. Nothing about that process changes how the medication is prescribed in the meantime.
What Schedule III means, in plain English
The DEA schedule is not a statement about how well a drug works or how dangerous it is to the person taking it as prescribed. It is a set of federal handling rules, and for patients the differences are mostly logistical.
Schedule II, where Adderall, Vyvanse, Ritalin, Concerta, Focalin, and Azstarys live, is the tightest tier of commercially available medicine:
- No refills. Every fill requires a new prescription from the prescriber.
- Prescriptions cannot be called in, with narrow exceptions; a written or electronic order is generally required.
- Pharmacies face stricter storage, recordkeeping, and quota rules, which is one reason a pharmacy may be out of stock or decline to fill.
- Telehealth and cross-state prescribing are more constrained.
Schedule III is one step down, and the practical differences are real:
- Refills are permitted: a single prescription may be refilled up to five times within six months of the date it was written.
- Prescriptions are easier to transmit, including by phone in many circumstances, and there are fewer federal barriers around telehealth.
- Pharmacy logistics are simpler, since Schedule III products are not bound by the same manufacturing quotas and stock constraints.
For someone who has taken the same dose of the same stimulant for three years, that first bullet is the whole story. Instead of a monthly renewal before the bottle runs out, one prescription can cover a stable patient for months.
What does not change: Simtriyo is still a controlled substance with a boxed warning for abuse, misuse, and addiction. Prescribers, pharmacies, distributors, and manufacturers must be DEA-registered, must store it securely, and must keep records and inventories. Patients taking it under a lawful prescription are not subject to any of those requirements, but they also cannot share it, stockpile it, or fill it early.
What Simtriyo is and what it does
Simtriyo is centanafadine, the first member of a class called NDSRIs: norepinephrine, dopamine, serotonin reuptake inhibitors. It blocks the reuptake of all three of those neurotransmitters, leaving more of each available in the brain pathways that govern attention, impulse control, and behavioral regulation.
The "triple" is the interesting part. Amphetamines (Adderall, Vyvanse, Dexedrine) primarily force the release of dopamine and norepinephrine and also block their reuptake. Methylphenidate (Ritalin, Concerta, Focalin) blocks reuptake of dopamine and norepinephrine. Both leave serotonin essentially alone. Centanafadine adds serotonin, which is a genuinely different pharmacological footprint in a space that has not seen a new mechanism since atomoxetine arrived in 2002.
The DEA, the FDA, and Otsuka all classify Simtriyo as a CNS stimulant. It is not a non-stimulant like Strattera or guanfacine, and it is not a supplement or a gentler natural alternative. It is a stimulant that happens to work through a different door.
How it is taken:
- A once-daily extended-release capsule, taken in the morning, with or without food.
- Swallowed whole. If that is difficult, the capsule can be opened and the contents sprinkled onto one tablespoon of applesauce or yogurt, or stirred into one tablespoon of orange juice, then swallowed immediately without chewing.
- Avoid alcohol at the time of the dose and for two hours afterward.
- Adults start at 210 mg and may go up to 280 mg. Adolescents 13 to 17 take 280 mg. Children 6 to 12 are dosed by weight, from 140 mg at 20 to 35 kg up to 280 mg above 50 kg.
- Not recommended under age 6, under 20 kg, or in severe liver impairment.
What the trials showed
Approval rested on four randomized, double-blind, placebo-controlled Phase 3 trials.
- Adults: two pivotal studies measured symptoms with the Adult ADHD Investigator Symptom Rating Scale. Both dose groups beat placebo significantly, with improvement visible by week one and maintained through the six-week study period.
- Children 6 to 12: on the ADHD Rating Scale-5, the approved weight-based dose produced roughly a 5.6-point greater reduction in symptoms than placebo at six weeks.
- Adolescents 13 to 17: the 280 mg dose produced roughly a 4.4-point greater reduction than placebo.
- Anxiety comorbidity: a Phase 3b study in adults with ADHD and co-occurring anxiety also met its primary endpoint. Full results have not yet been presented, so treat that finding as promising rather than proven.
Two honest caveats. First, the 140 mg dose did not separate from placebo in the pediatric trials, which is why it is not a starting dose for adolescents or adults. Second, and more important, Simtriyo has never been compared directly against an amphetamine or methylphenidate in a head-to-head trial. We cannot say it works better. We can say it works, through a different mechanism, in a population that has needed a different mechanism for a long time.
How it differs from Adderall and Ritalin
- Mechanism: triple reuptake inhibition of norepinephrine, dopamine, and serotonin, versus dopamine and norepinephrine release (amphetamines) or reuptake blockade (methylphenidate).
- Federal schedule: Schedule III versus Schedule II, meaning refills and easier transmission.
- Dosing: one extended-release capsule each morning; there is no immediate-release version and no multiple-times-a-day schedule.
- Rash: skin rash appears notably more often than with traditional stimulants, particularly in younger patients. The 210 mg capsule also contains FD&C Yellow No. 5 (tartrazine), which matters if you have a dye sensitivity.
- Serotonin interactions: because it raises serotonin, it should not be combined with an MAOI, and combining it with SSRIs, SNRIs, triptans, tramadol, or other serotonergic drugs carries a risk of serotonin syndrome. Many adults with ADHD also take an antidepressant, so this deserves a real conversation rather than a checkbox.
- Cardiovascular caution: unchanged. It still raises blood pressure and heart rate and should be avoided in structural heart disease, cardiomyopathy, serious arrhythmia, or coronary artery disease.
Who it might be best for
This is where a clinician's judgment matters more than a press release. Based on the mechanism and the trial data, the patients most likely to be considered are:
- Adults who did not tolerate an amphetamine or methylphenidate. Jitteriness, irritability, a hard afternoon crash, appetite loss, or insomnia that never settled are common reasons people stop stimulants that otherwise worked.
- Adults with coexisting anxiety. The serotonin component and the Phase 3b anxiety study are the most interesting signal here, even if the data is not yet fully public. Traditional stimulants can amplify anxiety in exactly these patients.
- Adults for whom the Schedule II refill treadmill is a genuine barrier. Frequent travel, relocating between states, a telehealth-only arrangement, or a pharmacy that keeps running short.
- People who want to avoid amphetamines specifically, for personal, occupational, or prior-experience reasons, while still wanting stimulant-level treatment.
It is probably not the right first choice for someone who has never tried a generic stimulant and whose insurance covers one, given brand-only pricing and the absence of long-term data. It is not appropriate for people with serious cardiac disease, for children under 6 or under 20 kg, or for anyone with a personal or family history of suicidality without very careful monitoring, given the pediatric boxed warning. And if you are stable on a Schedule II stimulant that is working, there is no clinical reason to switch.
Is there a generic?
No. Centanafadine is the generic name, Simtriyo is the brand, and Otsuka is the only manufacturer. There are no generic versions, no authorized generic, and no therapeutic equivalent at the pharmacy counter.
As a new chemical entity, centanafadine carries years of market exclusivity layered on top of its patents, so a generic is not expected any time soon. In practical terms that means brand pricing, likely prior authorization, and formulary placement that will vary by plan and will shift over the next year as insurers update their lists. Manufacturer copay assistance and cash-pay options are usually the levers worth checking, and the cost conversation should happen before a prescription is written, not after.
Safety, stated plainly
Simtriyo carries two boxed warnings, the FDA's most serious tier:
- Suicidal ideation and behaviors in pediatric patients 6 and older. Higher rates occurred in children 6 to 12 treated with Simtriyo than with placebo. Any child on this medication should be watched closely for changes in mood or behavior, especially early in treatment and after dose changes.
- Abuse, misuse, and addiction. Like all CNS stimulants, it can be misused, and misuse can cause overdose and death.
It is contraindicated with an MAOI, or within 14 days of stopping one, and in anyone with a history of pheochromocytoma. Other risks to know: increased blood pressure and heart rate, new or worsening psychotic or manic symptoms, serious allergic reactions including anaphylaxis and angioedema, growth suppression in children, peripheral vasculopathy including Raynaud's phenomenon, serotonin syndrome, and new or worsening tics.
One more thing that belongs in an honest article: this is a newly approved drug. Long-term and real-world data are limited by definition, and post-marketing experience over the next several years will tell us things the trials could not. That is a consideration to weigh, not a reason to dismiss an option that some patients have been waiting for.
What this means for patients at PracticeRx
We are a psychiatry practice first, and our job is not to prescribe the newest thing. It is to pick the thing most likely to work for you.
- Simtriyo is now a legitimate option to discuss, particularly for adults who have not done well on the two older drug families.
- Because it is Schedule III, a stable dose can be covered by one prescription with refills, which removes a recurring logistical burden.
- We verify benefits and work through prior authorizations before your first fill, so you know your actual cost rather than a surprise at the pharmacy counter.
- We can prescribe it by telehealth in every state where we are licensed, which matters for a medication that finally makes cross-state psychiatric care practical.
If you would like to talk through whether Simtriyo is worth considering alongside, or instead of, what you are taking now, start here.
The bottom line
A first-in-class drug got a lower controlled-substance schedule, and both facts are good news for people with ADHD. Schedule III means refills, less friction, and easier telehealth. A triple reuptake inhibitor means a mechanism that does not rely on amphetamine or methylphenidate, with the serotonin component offering something the older drugs never did.
What it does not mean is that Simtriyo is a better stimulant. It was never tested head to head against Adderall or Ritalin. Its trial effect sizes are real but modest. It carries boxed warnings, it will be expensive and brand-only, and its long-term profile is still being written. It is a genuinely new option, not a replacement for the ones that already work.
Medically reviewed by Clay Hall, NP, PhD, MBA. As of November 2026. Dosing, availability, and insurance coverage for newly launched medications change quickly; confirm details with your prescriber and pharmacy.
Sources
- Schedules of Controlled Substances: Placement of Centanafadine in Schedule III, Federal Register, October 30, 2026
- Simtriyo (centanafadine) prescribing information, FDA
- Otsuka announces FDA approval of Simtriyo, July 24, 2026
